Edit
Centauri Therapeutics Limited
http://www.centauritherapeutics.com/Last activity: 24.02.2026
Active
Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.
The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.
The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).
Centauri Therapeutics is based at Discovery Park, Kent. For more information about the company please visit www.centauritherapeutics.com
The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.
The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).
Centauri Therapeutics is based at Discovery Park, Kent. For more information about the company please visit www.centauritherapeutics.com
Location: United Kingdom
Employees: 11-50
Total raised: $50.12M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | NCL Techno... | ncltv.co.u... |
| - | NCL Invest... | nclim.co.u... |
| 24.02.2026 | AMR Action... | amractionf... |
| 17.07.2021 | CARB-X | carb-x.org |
| - | Renaissanc... | rcpinvest.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 24.02.2026 | Series A | $8.09M | AMR Action... |
| 07.08.2025 | - | $5.1M | CARB-X |
| 25.02.2022 | Series A | $32.68M | - |
| 19.01.2016 | - | $4.25M | - |
Mentions in press and media 11
| Date | Title | Description |
| 24.02.2026 | Centauri Therapeutics Raises £6M in Series A Extension Funding | Centauri Therapeutics, an Alderley Park, UK-based immunotherapy company, raised £6M in Series A extension funding. The round was led by AMR Action Fund. The raise brought the total amount to £30M. The company intends to use the funds to sup... |
| 24.02.2026 | Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate | Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections Investment from the world’s largest venture capital fund focused exclusively on a... |
| 07.08.2025 | Centauri Therapeutics: $5.1 Million Raised From CARB-X | Centauri Therapeutics, an immunotherapy company, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has granted an additional $5.1 million to support the development of its lead compound. Thi... |
| 30.07.2025 | Centauri Secures $5.1M CARB-X Boost for Lifesaving Antimicrobial Trials | Centauri Therapeutics secured $5.1 million from CARB-X, pushing its ABX-01 program towards human trials. Total CARB-X support now reaches $12.3 million. This crucial investment drives ABX-01, an Alphamer-based broad-spectrum antimicrobial, ... |
| 29.07.2025 | Centauri gets $5.1M from CARB-X to advance ABX-01 to human trials | UK-based Centauri Therapeutics, an immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas, has secured an additional $5.1 million in funding from CARB-X. This brings CARB-X’s total s... |
| 29.07.2025 | Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials | CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in hum... |
| 25.02.2022 | Centauri Therapeutics closes £24 million GBP Series A investment round | London, UK, 16 February 2022: Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, today announced the close of its £24 million GBP (c. 32 ... |
| 18.02.2022 | Centauri Therapeutics closes £24 million GBP Series A investment round | Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announces the close of its £24 million GBP (c. 32 million USD) Series A investment rou... |
| 02.03.2016 | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited 02-03-2016 Horizon Discovery Group plc, the leading international gene editing company, announces today that it has formed an immuno-oncology joint venture, Avvi... |
| 19.01.2016 | Centauri Therapeutics Raises £3M in Funding | Centauri Therapeutics Ltd, a Sandwich, UK-based biotechnology company focused on the treatment of infectious diseases, raised £3m in funding. Backers included Animatrix Capital LLP, a regional investment fund, and private investors. The com... |
Show more